SAN DIEGO, Sept. 28 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:
The Fourth Annual JMP Securities Healthcare Focus on Monday, October 5, 2009 at 4:30 p.m. Eastern Time at the New York Palace Hotel in New York City.
BIOCOM's 4th Annual Investor Conference on Monday, October 26, 2009 at 10:30 a.m. Pacific Time at the Hyatt Regency La Jolla in San Diego, California.
Live audio webcasts of this presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com, under the investors section. Replays of these presentations will be available at the same location for 30 days following the meeting.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Contacts
Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736
Porter Novelli Life Sciences
Jason I. Spark, Vice President
619-849-6005
